Y-mAbs Therapeutics, Inc.

NasdaqGS:YMAB Stock Report

Mkt Cap: US$206.1m

Y-mAbs Therapeutics Financial Health

How is Y-mAbs Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: YMAB's short term assets ($133.2M) exceed its short term liabilities ($32.0M).

Long Term Liabilities: YMAB's short term assets ($133.2M) exceed its long term liabilities ($4.0M).


Debt to Equity History and Analysis

Debt Level: YMAB is debt free.

Reducing Debt: YMAB has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: YMAB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: YMAB has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 27.7% each year.


Discover healthy companies